Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

Hemophilia News Today compiled a summary of the 10 most read hemophilia stories of 2024, with links to the individual items.

The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes ...

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce ...

The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator ...

Columnist Jennifer Lynne knows that finding a sense of community can be challenging, but she's also learned it's worth it.

Sangamo Therapeutics (SGMO) stock plunged as Pfizer (PFE) ends collaboration on hemophilia A gene therapy. Find out the ...

After more than four decades of infusing himself with the blood clotting factor his body can’t make, Chad Stevens decided it ...

Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...

injection for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years and older with hemophilia A (congenital factor VIII deficiency ...

Hemophilia A ... to spontaneous and severe bleeding after injuries or surgery. Sangamo said it remains focused on advancing its other therapy for the inherited disorder Fabry disease toward ...